SCHEMBL20129348

SCHEMBL20129348

c1ccc(-c2ccc3c(c2)[nH]c2ccncc23)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.65
▸ ACHE P22303 4/20 0.64
▸ KIF11 P52732 1/20 0.55
▸ IMPDH2 P12268 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ GABRP O00591 1/20 0.50
▸ GABRD O14764 1/20 0.50
▸ IKBKB O14920 1/20 0.50
▸ AURKA O14965 1/20 0.50
▸ CHUK O15111 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ PIM1 P11309 1/20 0.50
▸ TOP1 P11387 1/20 0.50
▸ GABRA1 P14867 1/20 0.50
▸ IDO1 P14902 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ GABRB1 P18505 1/20 0.50
▸ GABRG2 P18507 1/20 0.50
▸ MAOA P21397 1/20 0.50
▸ MAOB P27338 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16610292 0.89 MAPT (0.63) MAPTACHEKIF11KDM4EGABRP
SCHEMBL22906844 0.84 MAPT (0.65) MAPTACHEKIF11KDM4EGABRP
SCHEMBL533285 0.82 TNKS2 (0.61) MAPTKIF11IMPDH2KDM4EALDH1A1
SCHEMBL29533133 0.82 TNKS2 (0.61) MAPTKIF11IMPDH2KDM4EALDH1A1
SCHEMBL19269013 0.82 ACHE (0.56) MAPTACHEKIF11KDM4EGABRP
Carbazole SCHEMBL28221373 0.81 AHR (0.61) KIF11GABRPGABRDALDH1A1GABRA1
SCHEMBL20290655 0.81 AHR (0.61) KIF11GABRPGABRDALDH1A1GABRA1
SCHEMBL29724221 0.81 AHR (0.61) KIF11GABRPGABRDALDH1A1GABRA1
SCHEMBL1900394 0.81 AHR (0.61) KIF11GABRPGABRDALDH1A1GABRA1
SCHEMBL30959744 0.81 AHR (0.61) KIF11GABRPGABRDALDH1A1GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 — — WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 — — US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 MAPT 5/4885ACHE 3345/4885KIF11 2071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback